These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 1782327)

  • 41. Effect of sera from myasthenia gravis patients and of alpha-bungarotoxin on acetylcholinesterase during in vitro neuromuscular synaptogenesis.
    de la Porte S; Ragueh F; Eymard B; Courbin P; Chapron J; Koenig J
    J Neurol Sci; 1993 Jul; 117(1-2):92-102. PubMed ID: 8410074
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identification of a cytoplasmic region of the Torpedo nicotinic acetylcholine receptor alpha-subunit by epitope mapping.
    Pedersen SE; Bridgman PC; Sharp SD; Cohen JB
    J Biol Chem; 1990 Jan; 265(1):569-81. PubMed ID: 1688436
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Monoclonal antibodies raised against human acetylcholine receptor bind to all five subunits of the fetal isoform.
    Jacobson L; Beeson D; Tzartos S; Vincent A
    J Neuroimmunol; 1999 Aug; 98(2):112-20. PubMed ID: 10430044
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anti-idiotypic T cells in early stages of myasthenia gravis: increase in the number and prevalence correlated to clinical improvement in patients.
    Yi Q; Pirskanen R; Lefvert AK
    Scand J Immunol; 1996 Dec; 44(6):630-7. PubMed ID: 8972746
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Monoclonal antibodies that distinguish between normal and denervated human acetylcholine receptor.
    Whiting PJ; Vincent A; Schluep M; Newsom-Davis J
    J Neuroimmunol; 1986 May; 11(3):223-35. PubMed ID: 3082932
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Enzyme-linked immunosorbent assay for antibody against the nicotinic acetylcholine receptor in human myasthenia gravis.
    Kawanami S; Tsuji R; Oda K
    Ann Neurol; 1984 Feb; 15(2):195-200. PubMed ID: 6367620
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor.
    Tzartos SJ; Barkas T; Cung MT; Mamalaki A; Marraud M; Orlewski P; Papanastasiou D; Sakarellos C; Sakarellos-Daitsiotis M; Tsantili P; Tsikaris V
    Immunol Rev; 1998 Jun; 163():89-120. PubMed ID: 9700504
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Detection and characterization of blocking-type anti-acetylcholine receptor antibodies in sera from patients with myasthenia gravis.
    Hara H; Hayashi K; Ohta K; Itoh N; Nishitani H; Ohta M
    Clin Chem; 1993 Oct; 39(10):2053-7. PubMed ID: 8403390
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anti-acetylcholine receptor idiotypes in myasthenia gravis analysed by rabbit anti-sera.
    Lang B; Roberts AJ; Vincent A; Newsom-Davis J
    Clin Exp Immunol; 1985 Jun; 60(3):637-44. PubMed ID: 4017289
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Suppression of development of experimental autoimmune myasthenia gravis with isogeneic monoclonal anti-idiotopic antibody.
    Agius MA; Richman DP
    J Immunol; 1986 Oct; 137(7):2195-8. PubMed ID: 3489757
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The ligand binding domain of the nicotinic acetylcholine receptor. Immunological analysis.
    Kachalsky SG; Aladjem M; Barchan D; Fuchs S
    FEBS Lett; 1993 Mar; 318(3):264-8. PubMed ID: 8440381
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anti-acetylcholine receptor (AChR) antibodies measurement in myasthenia gravis: the use of cell line TE671 as a source of AChR antigen.
    Somnier FE
    J Neuroimmunol; 1994 Apr; 51(1):63-8. PubMed ID: 8157737
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An alpha-bungarotoxin-binding sequence on the Torpedo nicotinic acetylcholine receptor alpha-subunit: conservative amino acid substitutions reveal side-chain specific interactions.
    McLane KE; Wu X; Conti-Tronconi BM
    Biochemistry; 1994 Mar; 33(9):2576-85. PubMed ID: 8117719
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Experimental models of myasthenia gravis: lessons in autoimmunity and progress toward better forms of treatment.
    Pachner AR
    Yale J Biol Med; 1987; 60(2):169-77. PubMed ID: 3495075
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chronic murine experimental myasthenia gravis: strength testing and serology.
    Pachner AR; Itano A; Ricalton N; Choe S
    Clin Immunol Immunopathol; 1991 Jun; 59(3):398-406. PubMed ID: 2029792
    [TBL] [Abstract][Full Text] [Related]  

  • 56. On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope.
    Atassi MZ; Oshima M; Deitiker P
    Crit Rev Immunol; 2001; 21(1-3):1-27. PubMed ID: 11642597
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Amino acid residues within the sequence region alpha 55-74 of Torpedo nicotinic acetylcholine receptor interacting with antibodies to the main immunogenic region and with snake alpha-neurotoxins.
    Wahlsten JL; Lindstrom JM; Conti-Tronconi BM
    J Recept Res; 1993; 13(6):989-1008. PubMed ID: 8510074
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interaction of monoclonal antibodies to Torpedo acetylcholine receptor with the receptor of skeletal muscle.
    Souroujon MC; Mochly-Rosen D; Gordon AS; Fuchs S
    Muscle Nerve; 1983 May; 6(4):303-11. PubMed ID: 6866010
    [TBL] [Abstract][Full Text] [Related]  

  • 59. T-cell vaccination in experimental myasthenia gravis: a double-edged sword.
    Kahn CR; McIntosh KR; Drachman DB
    J Autoimmun; 1990 Dec; 3(6):659-69. PubMed ID: 2150910
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Morphologic and immunologic studies in experimental autoimmune myasthenia gravis and myasthenia gravis.
    Trotter JL; Ringel SP; Cook JD; Engel WK; Eldefrawi ME; McFarlin DE
    Neurology; 1977 Dec; 27(12):1120-4. PubMed ID: 73154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.